The efficacy of vitrectomy combined with conbercept in the treatment of diabetic retinopathy

Abstract

Objective To evaluate the clinical efficacy of vitrectomy combined with intravitreal injection of conbercept in the treatment of proliferative diabetic retinopathy (PDR). Methods A prospective control study. The data of 86 eyes of 62 patients with PDR from Oct. 2016 to Dec. 2017 were analyzed. All cases were divided into two groups. The control group, 41 eyes of 31 cases, underwent vitrectomy only. The combined group, 45 eyes of 31 cases, underwent vitrectomy combined with intravitreal injection of conbercept. BCVA, macular area retinal thickness and central macular thickness(CMT) were measured before and 3, 6 months after surgery. The complications were recorded. Results The total effective rate of the combined group was better than that of the control group(95.56% vs 75.61%), the difference was statistically significant (χ2=5.5444, P=0.0185). BCVA (LogMAR) of the combined group were 1.13±0.19, 0.71±0.22 and 0.38±0.16 before and 3, 6 months after surgery. BCVA of control group was 1.12±0.18, 0.73±0.20 and 0.53±0.18, respectively. BCVA at 6 months after surgery in the combined group was better than that in the control group (t=4.091, P=0.0001). The differences in CMT, macular retinal thickness and postoperative complications were not significant between the two groups (P>0.05). Conclusion Vitrectomy combined with intravitreal injection of conbercept for the treatment of PDR is effective. Key words: Retinopathy, diabetic, proliferative; Vitrectomy; Conbercept; Visual function; Central macular thickness